Hong Kong stocks abnormal | Kangfang Biotech (09926.HK) rose nearly 5% AK154 single drug or in combination with Cardinale/Evosil as an adjuvant therapy for pancreatic cancer Phase I clinical trial completed the first drug administration.
According to the Securities Times app, Kangfang Biotech (09926.HK) rose nearly 5%, as of the time of writing, it has risen 4.72% to 119.9 Hong Kong dollars, with a trading volume of 3.1 billion Hong Kong dollars.
Latest
3 m ago
